Carolinas Wealth Consulting’s Neurocrine Biosciences NBIX Stock Holding History

Carolinas Wealth Consulting’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-11	Closed	-$1.18K	–	613
2025 Q1	$1.18K	Buy	11 +1	+10%	+$127	﹤0.01%	893
2024 Q4	$1.29K	Buy	10 +4	+67%	+$495	﹤0.01%	903
2024 Q3	$613	Hold	6	–	–	﹤0.01%	987
2024 Q2	$732	Buy	6 +1	+20%	+$137	﹤0.01%	950
2024 Q1	$684	Sell	5 -7	-58%	-$956	﹤0.01%	952
2023 Q4	$1.53K	Hold	12	–	–	﹤0.01%	772
2023 Q3	$1.29K	Buy	12 +7	+140%	+$737	﹤0.01%	788
2023 Q2	$440	Buy	5 +1	+25%	+$98	﹤0.01%	1014
2023 Q1	$405	Hold	4	–	–	﹤0.01%	1014
2022 Q4	$478	Buy	+4	New	+$469	﹤0.01%	998

Other funds holding NBIX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Carolinas Wealth Consulting's NBIX Position: Q2 2025 in Review

Carolinas Wealth Consulting sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 11 shares — an estimated $1.18K sold.

Carolinas Wealth Consulting first reported a position in NBIX in Q4 2022 and held it in 10 quarters. The position peaked at $1.53K in Q4 2023. 586 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

Carolinas Wealth Consulting reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
Carolinas Wealth Consulting sold 11 Neurocrine Biosciences shares in Q2 2025, an estimated $1.18K.
Carolinas Wealth Consulting first reported a position in Neurocrine Biosciences in Q4 2022 and held it in 10 quarters.
Carolinas Wealth Consulting's Neurocrine Biosciences position peaked at $1.53K in Q4 2023.
586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Carolinas Wealth Consulting's 13F filing for Q2 2025.